Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GLS.NSE
- Price
- 1100.60
- Stock movement down
- -32.80 (-2.89%)
- Company name
- Glenmark Life Sciences Limited
- Exchange
- (NSE ,
- Currency
- INR )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 134.86B
- Ent value
- 135.86B
- Price/Sales
- 6.12
- Price/Book
- 5.31
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 31.84
- Forward P/E
- 24.17
- PEG
- -
- EPS growth
- 9.95%
- 1 year return
- 44.87%
- 3 year return
- 35.42%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-12
DIVIDENDS
GLS.NSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 31.84 |
| Price to OCF | 511.72 |
| Price to FCF | 511.72 |
| Price to EBITDA | 77.40 |
| EV to EBITDA | 77.97 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6.12 |
| Price to Book | 5.31 |
| EV to Sales | 6.16 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 122.53M |
| EPS (TTM) | 34.43 |
| FCF per share (TTM) | 2.14 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 22.05B |
| Gross profit (TTM) | 10.62B |
| Operating income (TTM) | 5.55B |
| Net income (TTM) | 4.24B |
| EPS (TTM) | 34.43 |
| EPS (1y forward) | 45.54 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 48.18% |
| Operating margin (TTM) | 25.19% |
| Profit margin (TTM) | 19.21% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.46B |
| Net receivables | 7.75B |
| Total current assets | 20.96B |
| Goodwill | 0.00 |
| Intangible assets | 172.70M |
| Property, plant and equipment | 0.00 |
| Total assets | 30.85B |
| Accounts payable | 3.98B |
| Short/Current long term debt | 159.77M |
| Total current liabilities | 4.64B |
| Total liabilities | 5.46B |
| Shareholder's equity | 25.38B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 263.54M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | 263.54M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 16.68% |
| Return on Assets | 13.73% |
| Return on Invested Capital | 16.67% |
| Cash Return on Invested Capital | 1.04% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1136.00 |
| Daily high | 1136.25 |
| Daily low | 1094.00 |
| Daily Volume | 48K |
| All-time high | 1310.90 |
| 1y analyst estimate | 1138.60 |
| Beta | 0.16 |
| EPS (TTM) | 34.43 |
| Dividend per share | - |
| Ex-div date | 17 Oct 2023 |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| GLS.NSE | S&P500 | |
| Current price drop from All-time high | -16.04% | -7.99% |
| Highest price drop | -51.05% | -56.47% |
| Date of highest drop | 28 Feb 2023 | 9 Mar 2009 |
| Avg drop from high | -24.10% | -11.07% |
| Avg time to new high | 35 days | 12 days |
| Max time to new high | 605 days | 1805 days |
COMPANY DETAILS
Marketcap
134.86B
Marketcap category
Large-cap
Description
Glenmark Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company's APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Nirma Limited.
Employees
2014
Investor relations
-
SEC filings
CEO
Country
India
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found